Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death. Recent recommendations from the GOLD report emphasize the diagnosis of COPD and treatment planning based on a combination of lung function metrics, exacerbation history, and patient-reported symptoms. It is recommending the use of triple combination therapy (ICS+LABA+LAMA) such as BREZTRI/TRIXEO as one of the options in Group E patients. While BGF has demonstrated efficacy in controlled clinical trials, real-world evidence is needed to assess its impact on daily patient outcomes and quality of life. The iCHOROS study is a real-world, international, multicenter, observational study aiming to evaluate changes in clinical and patient-reported outcomes in adults with moderate to severe COPD treated with BGF for 12 months in routine care settings across Latin America, Asia, and the Middle East \& Africa. The study will provide valuable insights into the effectiveness and patient experience of BGF therapy in diverse, real-world populations

Chronic Obstructive Pulmonary Disease poses a major health challenge globally and is currently the third leading cause of death worldwide, resulting in approximately 3.23 million deaths annually. The impact of COPD is particularly pronounced in low- and middle-income countries where healthcare resources may be limited. COPD is characterized by a progressive decline in lung function, frequent exacerbations, and high morbidity and mortality rates. Exacerbations, which are acute worsening events of respiratory symptoms, play a critical role in disease progression. Hospitalized severe exacerbations markedly increase the risk of further exacerbations, a rapid decline in health status, and high short-term mortality rates. Roughly 20% of patients at GOLD stage 2 experience frequent exacerbations necessitating additional interventions, with risk increasing in GOLD stages 3 and 4. Recent clinical guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) emphasize a multidimensional assessment, incorporating lung function, prior exacerbation history, and patient-reported symptoms to guide treatment. The overall goal of COPD pharmacologic therapy is to reduce symptoms (including dyspnea), prevent exacerbations, improve exercise tolerance, and enhance quality of life. Triple inhaled therapy, consisting of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and long-acting β2-agonist (LABA), is recommended for patients in GOLD Group E who continue to experience exacerbations despite dual therapy. This approach has demonstrated beneficial effect in reducing mortality among high-risk, symptomatic COPD patients. Breztri/Trixeo (BGF) is a fixed-dose triple combination of budesonide (ICS), glycopyrrolate (LAMA), and formoterol fumarate (LABA), administered via a metered dose inhaler utilizing Aerosphere™ delivery technology. BGF received regulatory approval from the FDA in July 2020 and the EMA in December 2020, based on phase III randomized controlled trials (RCTs) that established its efficacy in improving lung function and reducing moderate/severe exacerbations. These trials primarily measured lung function and exacerbation rates and also included secondary endpoints evaluating patient-reported outcomes (PROs). Despite these findings, there is a need for real-world evidence (RWE) to better understand the effectiveness, safety, and patient experience of BGF outside the controlled environment of RCTs. The importance of capturing PROs-such as the COPD Assessment Test (CAT) and modified Medical Research Council (m-MRC) dyspnea scale-in both clinical trials and real-world studies is increasingly recognized in the literature and reflected in current GOLD recommendations. Observational, patient-centric studies in routine clinical practice can provide complementary insights to RCTs, particularly through direct and timely collection of PRO data. Such studies elucidate the real-life impact of COPD and its management on da trial.show_full_description

Inclusion Criteria: The study will include patients who were prescribed BGF, but not yet initiated, according to the label (SmPC) and local market reimbursement criteria. Patients will only be included in the study if they meet the following inclusion criteria: 1. Patients diagnosed with COPD, at least 12 months before baseline, as assessed per physician's routine practice or as documented in the patient's chart. 2. Male or female patients aged over 30 years and under 80 years at the time of enrolment. 3. Patients providing a written Informed Consent\* prior to inclusion to the study. \*Prescription of BGF should be prior to the signed informed consent and the decision to prescribe this therapy is clearly separated from the physician's decision to include the patient in the current study. 4. Patients able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol. Exclusion Criteria: Patients who meet any of the following criteria will not be eligible to participate in the study: 1. Patients with COPD due to documented α-1 antitrypsin deficiency. 2. Patients with recent (≤3 months) major cardiac or pulmonary events that required hospitalization (e.g., myocardial infarction, pulmonary embolism). 3. Patients previously treated with triple fixed-dose combination therapies 12 months before the screening visit or treated with Multiple Inhaled Triple Therapy (MITT) within the last 3 months before the screening visit. 4. Patients hospitalized due to COPD exacerbations within the last 30 days prior to enrolment. 5. Currently pregnant (or intending to become pregnant), breastfeeding, or lactating women. 6. Patients with a current diagnosis of asthma, active tuberculosis, lung cancer or lung metastasis, significant bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases, or other active clinically significant pulmonary diseases. 7. Patients currently participating in a non-interventional observational trial that might, in the investigator's opinion, influence the assessment for the current study or participation in any interventional trial in the last 30 days prior to enrolment. 8. Patients with respiratory tract infection (including COVID-19 infection) ) that has not resolved ≤30 days prior to BGF MDI initiation and those exhibiting persistent long-COVID symptoms are excluded from the study.